Throughout the second Trump administration, the NIH has frozen billions of dollars in research funding to universities. Those ...
Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...
One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries - - Both Applications Will Be Assessed in Parallel ...
Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Dr Ray O’Connor takes a look at recent clinical articles on the importance of promoting vaccines for Measles, HIV, Gonorrhoea ...
A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering the sugars on their surface, hindering the host immune system and avoiding ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
Advancements in HIV/AIDS research, drug development, and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check ...
On World AIDS Day, advocates warn federal cuts could reverse progress. Carole Treston had been a nurse early in her career when she and her mother traveled to Washington, D.C., and saw the AIDS ...
On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results